Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center

Improved surgical, radiation and systemic therapies clearly have a positive impact on OS of women with EBC (EBCTCG 2015). However, it is still a matter of debate if survival of patients with MBC has equally improved. Since the 1990s, many new agents were introduced in the clinical care of MBC. These include taxanes, aromatase inhibitors, fulvestrant, capecitabin, vinorelbin, trastuzumab, liposomal doxorubicin, carboplatin, bevacizumab and lapatinib. Supportive therapy was optimized by recombinant granulopoiesis and erythropoiesis stimulating growth factors, and the morbidity of bone metastases was reduced by the use of bisphosphonates and denosumab. Recently, eribulin, everolimus, pertuzumab, trastuzumab emtansine (T-DM1), palbociclib, ribociclib and abemaciclib as well as atezolizumab, further expanded treatment options. This impressive therapeutic armamentarium heavily impinges on the OS outcome of randomized clinical trials conducted with new agents or combinations in earlier line treatment of MBC, as multiple options for postprogression therapy are available.

Until 2018 only very few drugs were able to demonstrate an OS benefit in clinical trials of MBC: exemestane was superior to megestrol acetate, docetaxel was more active than mitomycin/vinblastine and docetaxel plus capecitabin were more effective than docetaxel alone. In HER2-positive MBC, chemotherapy plus trastuzumab led to better survival than chemotherapy alone. Docetaxel/trastuzumab was further improved by the addition of pertuzumab and T-DM1 showed better overall survival compared to physician’s choice treatment in heavily pretreated patients (Kaufmann et al. 2000; Nabholtz et al. 1999; O’Shaughnessy et al. 2002; Slamon et al. 2001; Baselga et al. 2012; Verma et al. 2012). Still, some of these few positive studies were criticized because of clearly suboptimal second and third line treatments following progression on study therapy (O’Shaughnessy et al. 2002; Feher et al. 2005).

Recently, a significant survival benefit for a new agent could be demonstrated in MBC: Patients with hormone receptor positive tumors had improved survival with endocrine therapy (ET) plus a CDK4/6 inhibitor compared to ET alone (Im et al. 2019; Slamon et al. 2019; Sledge et al. 2019), and nab-Paclitaxel (nab-P) plus Atezolizumab was shown to be superior to nab-P alone in a defined subgroup of patients with triple negative MBC (TNBC) (Schmid et al. 2018).

Most phase III studies leading to approval of new MBC drugs have relied on superiority in surrogate endpoints such as progression-free survival (PFS). Examples include bevacizumab, fulvestrant, aromatase inhibitors, everolimus, eribulin and CDK4/6 inhibitors. Assumable, this is explained by a dilution of the effect of the respective study drug on OS because of multiple effective options for next-line therapy.

Registries of comprehensive cancer centers (CCCs) may provide a useful resource for the analysis of trends of MBC mortality over extended periods, which correlate with the availability of new therapeutic options. While patient populations treated at CCCs may be positively selected, the high level of expertise and specialization of physicians and nurses, as well as the rapid access to diagnostic and therapeutic innovations assures high quality of care. Hence, relative changes in long-term outcomes that are obtained by a stable interdisciplinary team of MBC experts are well suited to detect the survival impact of therapeutic innovations that are introduced on specific periods. Examples for such analyses have been published from several major CCCs focusing on patients with secondary (Giordano et al. 2004; Chia et al. 2007; Sundquist et al. 2017) or de novo (Dawood et al. 2015; Ruiterkamp et al. 2011; Andre et al. 2004) MBC. These studies have demonstrated a stepwise improvement of OS over several decades. However, additional studies failed to demonstrate OS improvements for the entire population of MBC patients (Nakano et al. 2015; Tevaarwerk et al. 2013) or even suggested a trend for the deterioration of OS (Ufen et al. 2014; Hölzel et al. 2017).

Against this background, we conducted a long-term analysis of survival outcomes of women with MBC treated by the breast cancer team at the Department of Medical Oncology of the West German Cancer Center from 1990 to 2009.

In the current data set, we have observed an effect of year of diagnosis of MBC on OS. This is in line with findings from other high volume and expertise centers demonstrating a modest but significant increase in survival over time among patients with MBC. Giordano et al. published a seminal study of patients treated at the MD Anderson Cancer Center. Survival of 834 patients with recurrent breast cancer improved from 1974 to 2000 with 1% reduction in the risk of death for each successive year (2003). A study group from British Columbia found a relative prolongation of approximately 30% in OS for 2.150 patients with MBC diagnosed between 1991 and 2001 (Chia et al. 2007). A Swedish study group demonstrated improved survival from 13 to 33 months and 5YS from 10 to 27% for 784 patients diagnosed with MBC from 1985 to 2014 (Sundquist et al. 2017). However, not all of the prior analyses were adjusted for DFI and other covariates. Several major CCCs focused on patients with de novo MBC also reporting an improvement of OS for the entire population (Ruiterkamp et al. 2011; Dawood et al. 2015; Andre et al. 2004).

There is evidence that the most striking effect is given in the HER2 positive subset (Tevaarwerk et al. 2013; Nakano et al. 2015; Sundquist et al. 2017), partly represented as “HR negative disease” because information regarding HER2 status was missing in some analyses (Tevaarwerk et al. 2013). Clearly, this subgroup of patients has shown an OS benefit obviously caused by the introduction of HER2-targeted therapies (Slamon et al. 2001; Dawood et al. 2010; Baselga et al. 2012).

In general, more patients were treated with systemic therapies in the neo-/adjuvant setting since the 1990s. This is consistent with the international trend of decline in breast cancer mortality in western countries (DeSantis et al. 2014; Carioli et al. 2017) which cannot only be contributed to the implementation of mammographic screening in the more recent years. On the other hand, the extensive use of systemic treatment in the neo-/adjuvant setting in recent years could have reduced the effectiveness of palliative systemic therapy in these groups, because a greater proportion of patients were no longer naïve for chemotherapy and endocrine treatment. Ufen et al. studied 1635 patients treated for MBC in three German cancer centers between 1980 and 2009. They failed to find an improvement but observed a decline of median OS over time which was associated with a shift towards more aggressive disease (2014). This corresponds with Hölzel et al. reporting a clear improvement of 5-year-survival in EBC over three decades, presumably caused by better perioperative systemic treatment leading to an extension of DFI. Paradoxically, this effect was accompanied by a reduction of median OS in patients with MBC (2017).

We here present 1033 consecutive patients with MBC treated between 1990 and 2009 at a major German comprehensive cancer center. No predefined sequence of treatment for metastatic breast cancer was applied. Treatment sequence was individualized as a function of prior treatment, tumor biology, the dynamics of metastasis, and patient preferences (particularly in relation to toxicities and treatment intervals) by a stable expert team.

Cohort 2 (1995–1999) was much larger than other cohorts. During this period our cancer center offered high-dose chemotherapy with autologous stem cell transplantation in clinical studies as part of the therapeutic concept (Bojko et al. 2004). This is probably the main reason why more patients were assigned to our clinic.

Patient characteristics were unequally distributed across the four cohorts regarding HR status, age and DFI. The growing proportion of patients with known HR positivity may rather be explained by the adoption of routine testing of HR expression than by a real change in the distribution of HR positivity over time.

The significant increase in age over time may partially reflect the longer DFI between diagnosis and treatment of the primary breast tumor and metastasis. This is consistent with well-recognized improvements of multimodal treatment of primary breast cancer. More generally, this trend of rising age may indicate that the increase in life expectancy at birth for the overall population is not lost on women with MBC.

We find significant and relevant improvement in OS from 24.2 months to 38.8 months over this period of two decades. Our analyses with respect to the time of presentation (4 cohorts of distinct 5-year periods) and established risk factors (age, HR status, DFI, site of metastasis) showed that the gain in OS slowed over time. After risk adjustment, accounting for fluctuations over time in the patient characteristics, a significant gain is shown for the years 1995–1999 when compared to 1990–1995, and a numerical, statistically non-significant but plausible gain for the period of 2000–2004 compared to 1995–1999. No further improvement is seen when cohort 4 (2005–2009) is compared to the immediately preceding cohort. However, the improvement in OS accrued in the first 15 years of the study sustains.

In agreement with Hölzel et al. (2017) our analyses showed a sustained increase of DFI over time from 25.9 (1990–1994) to 41.0 months (2005–2009), plausibly due to improvements in the primary treatment. Assuming the recurrent population is composed of more negatively selected cancer biologies, this could explain that increments in OS have become less profound over time despite of the introduction of new therapeutic agents in the treatment of MBC in Germany (1990–1994: paclitaxel; 1995–1999: docetaxel, letrozole, anastrozole; 2000–2004: exemestane, capecitabin, trastuzumab, fulvestrant, pegylated liposomal doxorubicin, gemcitabin; 2005–2009: bevacizumab, liposomal doxorubicin, lapatinib, nab-P).

We recognize that the current study has limitations. Some degree of bias may be attributed to the retrospective character of this analysis. Additionally, HER2 status was not included in our evaluation, because it was unknown in many patients treated for MBC in the nineties. Therefore a subsequent analysis regarding HER2 status of patients in cohorts 3 and 4 is planned soon. This will include a more recent cohort (2010–2014), too.

The strengths of this study include a large unselected patient population and extensive median follow-up time (median years: 2.53; range 1.30–4.49). OS results of the cohorts 3 (2000–2004; OS 36.5 months) and 4 (2005–2009; OS 37.8 months) are well in line with those reported from the prospective German TMK cohort study, namely median OS of 33.8 months reporting 1395 “real world” patients treated from 2007 to 2015 in various oncology practices and community hospitals in Germany (Fietz et al. 2017).

In sum, we report survival data of patients with MBC treated at the Department of Medical Oncology at the West German Cancer Center that show large improvements between 1990 and 2009. During this time, multiple effective anticancer agents that can palliate MBC have been introduced into routine practice. The rate of improvement, however, appears to have been slowing during the observation time of our study. This suggests either a negative selection of patients with recurrent breast cancer due to more effective perioperative therapy over time in EBC or a lesser impact of therapeutic innovations introduced in the most recent period. Since 2010, again many drugs were released in the treatment of MBC (eribulin, T-DM1, pertuzumab, everolimus, ribociclib, palbociclib, abemaciclib, atezolizumab) which hopefully will further improve survival with MBC.